Search - tctmd.com

Displaying 281 - 300 of 407

Sort: Relevancy | Date

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

News Daily News

Cardioversion Without Anticoagulation Appears Safe in Patients With Watchman

November 01, 2019

TCTMD’s Top 10 Most Popular Stories for October 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2019

October 31, 2019

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

Presentation

Impact of Preexisting and New-Onset A-fib on TAVR Outcomes

October 18, 2019

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

News Daily News

New-Onset A-fib Tied to Particularly Poor Outcomes After TAVR

October 18, 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

News Conference News TCT 2019

Watchman Adverse Events: Analysis Digs Into What’s Been Reported to the FDA

October 04, 2019

Presentation TCT Abstracts Posters 2019

In-hospital Outcomes of Transcatheter Aortic Valve Replacement in Patients with Atrial Fibrillation: Nationwide Database Analysis

Presenter: Fangcheng Wu

September 29, 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

News Conference News TCT 2019

Oral Anticoagulation After TAVR Doesn’t Reduce Ischemic Cerebral Lesions: AUREA

Michael O'Riordan

September 28, 2019

Enabling Early TAVR Patient Ambulation Outside the ICU With the Tempo Lead

Presentation TCT 2019

Enabling Early TAVR Patient Ambulation Outside the ICU With the Tempo Lead

Presenter: Stanley Chetcuti

September 26, 2019

The Tempo Lead: A New Standard of Care in Temporary Pacing

Presentation TCT 2019

The Tempo Lead: A New Standard of Care in Temporary Pacing

Presenter: Tamim Nazif

September 26, 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

News Conference News TCT 2019

TCT 2019: Pharmacotherapy in PCI, Head-to-Head Valves, YouTube Rappers, and More

September 19, 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

News Conference News ESC 2019

Reduced-Dose Rivaroxaban May Be an Option After LAA Occlusion, ADRIFT Hints

September 11, 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

News Conference News ESC 2019

LAA Occluders, NOACs Provide Similar Outcomes in High-risk A-fib Patients: PRAGUE-17

September 10, 2019

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

News Daily News

MIDAS Touch: Anatomic Strategy Dramatically Lowers Pacemaker Rate With Evolut Valves

Michael O'Riordan

August 29, 2019

#Selfies, Carrots, and Push-ups: A Defense of Social Media in Modern-Day Medicine

News Opinion Off Script

#Selfies, Carrots, and Push-ups: A Defense of Social Media in Modern-Day Medicine

Mamas Mamas, BMBCh

August 23, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

News Daily News

Antiplatelets Protective Post-TAVR in A-fib Patients: PARTNER II Data

August 21, 2019

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

Presentation

Antithrombotic Therapy and CV Outcomes After TAVR in A-fib Patients

August 20, 2019

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

News Daily News

No Volume-Outcome Link With Watchman for LAA Closure? Single-Center Study

Michael O'Riordan

August 19, 2019

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

News Daily News

Better Outcomes, Fewer Complications Among Higher-Volume MitraClip Sites

Michael O'Riordan

July 17, 2019

News Industry News

BIOTRONIK Receives FDA Clearance on Next-Gen Injectable Cardiac Monitor: BIOMONITOR III

July 08, 2019

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.